INGELHEIM, Germany & BALTIMORE, Md.--(BUSINESS WIRE)--Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) today announced a joint research and licensing collaboration focused on ...
Catechol-O-methyltransferase (COMT) inhibitors have long been recognised for their clinical utility in managing neurological disorders, most notably Parkinson’s disease. By impeding the enzymatic ...
Hosted on MSN
Common Medications for Parkinson’s Disease
Parkinson’s disease is a condition that damages dopamine-producing brain cells, leading to tremors, stiffness, and difficulty with balance and coordination. Medications for Parkinson’s disease aim to ...
A once-daily add-on therapy for Parkinson's disease (PD) used in Europe for years has now gained clearance in the U.S. with FDA approval of Ongentys (opicapone). The drug, an improvement upon generics ...
Dopamine agonists and dopamine reuptake inhibitors (DRIs) appear to have equal efficacy for Parkinson's disease (PD) and motor fluctuations uncontrolled by levodopa. However, some DRIs are more ...
It turns out there are a bunch of genes that can make it difficult for some people to eliminate toxins from the body—toxins from air pollution, pesticides, fragrances, mold, estrogen, parasites, and ...
A randomized clinical trial examined patient quality of life in Parkinson disease (PD) when adding different adjuvant therapies to levodopa to help control dyskinesia and a flaring of symptoms during ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results